Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon therapy in multiple myeloma]

M Micksche1

  • 1Abteilung für Agewandte und Experimentelle Onkologie, Universität Wien.

Wiener Medizinische Wochenschrift (1946)
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ribonucleotide reductase as one important target of [Tris(1,10-phenanthroline)lanthanum(III)] trithiocyanate (KP772).

Current cancer drug targets·2009
Same author

Vaults and the major vault protein: novel roles in signal pathway regulation and immunity.

Cellular and molecular life sciences : CMLS·2008
Same author

New cellular tools reveal complex epithelial-mesenchymal interactions in hepatocarcinogenesis.

British journal of cancer·2008
Same author

FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.

Oncogene·2008
Same author

Probiotic, as well as conventional yogurt, can enhance the stimulated production of proinflammatory cytokines.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2007
Same author

Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

Biochemical pharmacology·2007
Same journal

Necrotizing fasciitis of the thigh-a devastating sign of intestinal perforation.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Cerebral toxoplasmosis in patients with peripheral B-cell lymphoma : A case series and a literature review.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Post-pandemic rebound of rotavirus and adenovirus in pediatric gastroenteritis: a 6-year antigen-based surveillance study from Turkey.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Neuroaxis involvement in Chikungunya virus infection: a retrospective case series.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

A complicated case of a spinal Scedosporium apiospermum infection with a favorable outcome-case report.

Wiener medizinische Wochenschrift (1946)·2026
See all related articles

Recombinant interferons (rIFNs) offer a new therapeutic strategy for multiple myeloma, a B-cell malignancy. Interferon therapy can maintain chemotherapy-induced remissions and has relevance in induction therapy.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Context:

  • Multiple myeloma is a plasma cell malignancy.
  • Cytostatic therapy is the current standard treatment.
  • Prognosis depends on clinical stage and biological features.

Purpose:

  • To explore the therapeutic administration of recombinant interferons (rIFNs) in multiple myeloma treatment.
  • To evaluate the role of interferons in maintaining remissions and in induction therapy.

Summary:

  • Recombinant interferons (rIFNs) represent a novel therapeutic strategy for multiple myeloma.
  • IFN therapy has shown potential in maintaining chemotherapy-induced remissions (plateau phase).
  • Interferons, in combination with cytostatic agents, demonstrate therapeutic relevance in induction therapy.

Related Experiment Videos

Impact:

  • The integration of rIFNs signifies a new approach in managing multiple myeloma.
  • Interferon therapy may improve outcomes for patients with multiple myeloma.
  • Further research into IFN-based regimens could enhance treatment efficacy.